Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016710921> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2016710921 endingPage "731" @default.
- W2016710921 startingPage "731" @default.
- W2016710921 abstract "The inflammatory muscle diseases represent a group of rare autoimmune diseases of unknown etiology which can have an acute, subacute or chronic presentation. Polymyositis (PM), Dermatomyositis (DM) and Inclusion Body Myositis (IBM) are the largest group of acquired and potentially treatable inflammatory myopathies. Clinically these entities share the presence of symmetric proximal muscle weakness caused by muscle inflammation and necrosis, heralded by elevated serum muscle enzymes. Frequently there are extramuscular manifestations associated and the presence of myositis-specific auto-antibodies. Diagnosis is based on clinical findings, confirmed by laboratory examinations. The aim of the present study was to make a review of the demographic characteristics, main clinical features, laboratory findings (with emphasis on the importance of immunologic profile) and therapeutic strategies in patients with PM, DM and IBM in a Rheumatology Department. The population of this study was constituted by 32 patients diagnosed, submitted to medical therapy and followed in our center in a 5 year-period (January 2006 to December 2010). We diagnosed and managed 32 patients with inflammatory myopathies in this period; 25 females and 7 males. PM represented 57% of the cases, followed by DM (37%) and IBM (6%). The mean age at time of diagnosis was 48.3 years. CK and aldolase were, with one exception, elevated. 75% of the patients presented antinuclear antibodies, more frequently with a specificity anti-Jo-1 and anti-SSa. The most frequent presenting clinical was muscular weakness (65%) and 31 patients presented it at the time of diagnosis. Involvement of other organs besides muscle occurred in half of the patients, and the most frequently involved organ was the lung. 8 patients were successfully treated only with glucocorticoids with no recurrence of the symptoms; the others needed iv immunoglobulin or immunosuppressive therapy. We registered 4 deaths." @default.
- W2016710921 created "2016-06-24" @default.
- W2016710921 creator A5021645150 @default.
- W2016710921 creator A5026473621 @default.
- W2016710921 creator A5060748469 @default.
- W2016710921 creator A5073744944 @default.
- W2016710921 creator A5074596503 @default.
- W2016710921 date "2011-10-01" @default.
- W2016710921 modified "2023-10-18" @default.
- W2016710921 title "P5.25 Inflammatory myopathies – Characteristics of a population" @default.
- W2016710921 doi "https://doi.org/10.1016/j.nmd.2011.06.1054" @default.
- W2016710921 hasPublicationYear "2011" @default.
- W2016710921 type Work @default.
- W2016710921 sameAs 2016710921 @default.
- W2016710921 citedByCount "0" @default.
- W2016710921 crossrefType "journal-article" @default.
- W2016710921 hasAuthorship W2016710921A5021645150 @default.
- W2016710921 hasAuthorship W2016710921A5026473621 @default.
- W2016710921 hasAuthorship W2016710921A5060748469 @default.
- W2016710921 hasAuthorship W2016710921A5073744944 @default.
- W2016710921 hasAuthorship W2016710921A5074596503 @default.
- W2016710921 hasConcept C126322002 @default.
- W2016710921 hasConcept C137627325 @default.
- W2016710921 hasConcept C142724271 @default.
- W2016710921 hasConcept C149443304 @default.
- W2016710921 hasConcept C159654299 @default.
- W2016710921 hasConcept C163764329 @default.
- W2016710921 hasConcept C198451711 @default.
- W2016710921 hasConcept C203014093 @default.
- W2016710921 hasConcept C2776418732 @default.
- W2016710921 hasConcept C2777327098 @default.
- W2016710921 hasConcept C2778751314 @default.
- W2016710921 hasConcept C2779387793 @default.
- W2016710921 hasConcept C2780181341 @default.
- W2016710921 hasConcept C2781232998 @default.
- W2016710921 hasConcept C2908647359 @default.
- W2016710921 hasConcept C71924100 @default.
- W2016710921 hasConcept C90924648 @default.
- W2016710921 hasConcept C99454951 @default.
- W2016710921 hasConceptScore W2016710921C126322002 @default.
- W2016710921 hasConceptScore W2016710921C137627325 @default.
- W2016710921 hasConceptScore W2016710921C142724271 @default.
- W2016710921 hasConceptScore W2016710921C149443304 @default.
- W2016710921 hasConceptScore W2016710921C159654299 @default.
- W2016710921 hasConceptScore W2016710921C163764329 @default.
- W2016710921 hasConceptScore W2016710921C198451711 @default.
- W2016710921 hasConceptScore W2016710921C203014093 @default.
- W2016710921 hasConceptScore W2016710921C2776418732 @default.
- W2016710921 hasConceptScore W2016710921C2777327098 @default.
- W2016710921 hasConceptScore W2016710921C2778751314 @default.
- W2016710921 hasConceptScore W2016710921C2779387793 @default.
- W2016710921 hasConceptScore W2016710921C2780181341 @default.
- W2016710921 hasConceptScore W2016710921C2781232998 @default.
- W2016710921 hasConceptScore W2016710921C2908647359 @default.
- W2016710921 hasConceptScore W2016710921C71924100 @default.
- W2016710921 hasConceptScore W2016710921C90924648 @default.
- W2016710921 hasConceptScore W2016710921C99454951 @default.
- W2016710921 hasIssue "9-10" @default.
- W2016710921 hasLocation W20167109211 @default.
- W2016710921 hasOpenAccess W2016710921 @default.
- W2016710921 hasPrimaryLocation W20167109211 @default.
- W2016710921 hasRelatedWork W1510791998 @default.
- W2016710921 hasRelatedWork W1976912157 @default.
- W2016710921 hasRelatedWork W1984025776 @default.
- W2016710921 hasRelatedWork W2016710921 @default.
- W2016710921 hasRelatedWork W2049484723 @default.
- W2016710921 hasRelatedWork W2188897352 @default.
- W2016710921 hasRelatedWork W2243558930 @default.
- W2016710921 hasRelatedWork W2552302675 @default.
- W2016710921 hasRelatedWork W2754776100 @default.
- W2016710921 hasRelatedWork W4297900568 @default.
- W2016710921 hasVolume "21" @default.
- W2016710921 isParatext "false" @default.
- W2016710921 isRetracted "false" @default.
- W2016710921 magId "2016710921" @default.
- W2016710921 workType "article" @default.